Anatomic Pathology Service and Translational Hematopathology Lab, Hospital Universitario Marques de Valdecilla, Universidad de Cantabria, IDIVAL, Santander, Spain.
Pathologie (Heidelb). 2023 Dec;44(Suppl 3):136-139. doi: 10.1007/s00292-023-01258-6. Epub 2023 Nov 27.
Primary cutaneous CD30+ lymphoproliferative disorders (LPD) encompass a broad category of clonal T cell proliferations with varied clinical presentations. Classically, lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large cell lymphoma (ALCL) have been recognized as distinct clinicopathological entities according to their differing clinical features. Recently, a subset of LyP and both cutaneous and systemic ALCL have been shown to carry a DUSP22 translocation [1-3], a defining molecular feature for the novel entity "LyP with DUSP22t" [1]. In cutaneous biopsies, both primary cutaneous DUSP22-translocated ALCL and LyP with DUSP22 rearrangements are characterized by a biphasic pattern with significant small cell epidermotropism. A distinct protein expression profile with preserved T Cell Receptor (TCR) expression, positivity for CD30, LEF1, HLA, and CD58, and negativity for cytotoxic marker expression as well as phospho-STAT3 protein is consistently found in these cases.
原发性皮肤 CD30+淋巴增生性疾病(LPD)包括一大类具有不同临床表现的克隆性 T 细胞增生。经典地,蕈样肉芽肿(LyP)和原发性皮肤间变性大细胞淋巴瘤(ALCL)根据其不同的临床特征被认为是不同的临床病理实体。最近,已经表明 LyP 的一部分和皮肤和系统性 ALCL 都携带 DUSP22 易位[1-3],这是新型实体“具有 DUSP22t 的 LyP”的定义分子特征[1]。在皮肤活检中,原发性皮肤 DUSP22 易位的 ALCL 和具有 DUSP22 重排的 LyP 均表现为具有显著小细胞表皮亲嗜性的双相模式。在这些病例中,始终发现具有保存的 T 细胞受体(TCR)表达、CD30、LEF1、HLA 和 CD58 阳性、细胞毒性标志物表达和磷酸化 STAT3 蛋白阴性的独特蛋白表达谱。